Key Highlights

  • Third quarter net loss was USD 8.9 million, or USD 0.26 per share, versus USD 7.4 million, or USD 0.60 per share, a year earlier on a much larger share count.
  • Cash and cash equivalents reached USD 289.6 million at September 30, 2026, up from USD 48.3 million at December 31, 2025, after two Equity raises.
  • Operating expenses rose to USD 10.7 million from USD 7.6 million, with Research and Development at USD 5.1 million and general and administrative at USD 5.5 million.
  • Week 36 data showed a 35.3% mean SALT score reduction, and a registration-directed bempikibart program is planned for the first half of 2027.

Third-Quarter Loss Widens in Dollars, Narrows Per Share

Q32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases, filed its Quarterly Report for the period ended September 30, 2026 on November 4, 2026. The net loss for the quarter was USD 8.9 million versus USD 7.4 million, but the loss per share fell to USD 0.26 from USD 0.60 because weighted shares rose to 34.0 million from 12.2 million. Research and development was USD 5.1 million versus USD 3.6 million, mainly from higher bempikibart Manufacturing and clinical costs. Other income rose to USD 1.7 million from USD 0.2 million on higher average cash balances.

Two Raises Rebuild the Balance Sheet

The cash build came from financing. A private Placement on May 28, 2026 sold 6,725,000 shares at USD 8.00 for net proceeds of USD 53.4 million. A public offering on July 16, 2026 sold 6,027,399 shares at USD 18.25 plus pre-funded warrants, for net proceeds of USD 187.5 million. Shares outstanding were 29,892,127 at quarter end versus 12,858,047 at December 31, 2025, a dilution effect for existing holders. The company reported an accumulated Deficit of USD 230.5 million and stockholders' equity of USD 287.7 million at quarter end. The company repaid its remaining venture Debt of about USD 6.8 million on June 24, 2026, and it also holds an at-the-market sales agreement.

Bempikibart Data and the Path to a Registration Program

In SIGNAL-AA Part B, 40.0% of the 25 patients in the modified analysis, and 30.3% of all 33 enrolled, reached a SALT-20 response at Week 36. In the off-drug follow-up, 44% of 18 patients had a SALT-20 response at 16 weeks. Across all trials, bempikibart has been dosed in over 150 participants without Grade 3 or higher treatment-related adverse events. The company plans regulatory discussions in the fourth quarter of 2026 and intends to start a registration-directed program in the first half of 2027. Management expects its cash to fund operations through topline Phase 3 results of bempikibart, but not through approval. Q32 Bio (NASDAQ:QTTB) will need additional capital, and trial outcomes remain uncertain.

Where Things Stand

On the company's own estimate, yes for the next stage but not beyond it. Q32 Bio (NASDAQ:QTTB) says its USD 289.6 million of cash should cover operations through topline Phase 3 results of bempikibart, while it does not expect that cash to carry any program through regulatory approval. The key near-term markers are the fourth-quarter regulatory discussions, the first-half 2027 program start and open-label extension results expected in the second half of 2027.